Panagora Asset Management Inc. Has $115.25 Million Position in Eli Lilly and Company $LLY

Key Points

• Panagora Asset Management Inc. increased its holdings in Eli Lilly and Company by 1.9%, now owning 139,537 shares valued at approximately $115.25 million.
• Eli Lilly reported an earnings per share (EPS) of $6.31 for the last quarter, exceeding estimates by $0.72, with revenue of $15.56 billion reflecting a year-over-year increase of 37.6%.
• The company announced a quarterly dividend of $1.50 per share, resulting in an annualized dividend yield of 0.8%, with a payout ratio of 39.22%.

Panagora Asset Management Inc. raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 1.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 139,537 shares of the company's stock after buying an additional 2,630 shares during the period. Panagora Asset Management Inc.'s holdings in Eli Lilly and Company were worth $115,245,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. WestEnd Advisors LLC increased its stake in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $27,000. Citizens National Bank Trust Department increased its stake in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after buying an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $40,000. Finally, Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company in the 4th quarter valued at $43,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $732.41 on Friday. The company has a market capitalization of $693.20 billion, a price-to-earnings ratio of 47.87, a PEG ratio of 1.02 and a beta of 0.44. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a 50-day simple moving average of $748.68 and a 200 day simple moving average of $786.10. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $969.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is presently 39.22%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on LLY shares. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Leerink Partners restated a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Guggenheim lowered their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday. Finally, Daiwa America lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $950.17.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. Insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.